DB:BGL

Stock Analysis Report

Executive Summary

BioGaia AB (publ) develops, markets, and sells probiotic products with documented health benefits worldwide.


Snowflake Analysis

Flawless balance sheet with reasonable growth potential and pays a dividend.


Similar Companies

Share Price & News

How has BioGaia's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: BGL's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

8.5%

BGL

11.3%

DE Biotechs

7.1%

DE Market


1 Year Return

-19.4%

BGL

-5.1%

DE Biotechs

-17.5%

DE Market

Return vs Industry: BGL underperformed the German Biotechs industry which returned -5.1% over the past year.

Return vs Market: BGL underperformed the German Market which returned -17.5% over the past year.


Shareholder returns

BGLIndustryMarket
7 Day8.5%11.3%7.1%
30 Day-18.7%-8.0%-20.0%
90 Day-18.9%-22.7%-26.1%
1 Year-17.5%-19.4%-4.9%-5.1%-15.0%-17.5%
3 Year4.9%-1.6%17.7%16.4%-18.8%-25.8%
5 Year75.8%57.6%-5.1%-7.5%-17.9%-29.2%

Price Volatility Vs. Market

How volatile is BioGaia's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is BioGaia undervalued compared to its fair value and its price relative to the market?

34.1x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: BGL (€33.75) is trading above our estimate of fair value (€29.17)

Significantly Below Fair Value: BGL is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: BGL is poor value based on its PE Ratio (34.1x) compared to the Biotechs industry average (34x).

PE vs Market: BGL is poor value based on its PE Ratio (34.1x) compared to the German market (16.5x).


Price to Earnings Growth Ratio

PEG Ratio: BGL is poor value based on its PEG Ratio (2.2x)


Price to Book Ratio

PB vs Industry: BGL is overvalued based on its PB Ratio (12.6x) compared to the DE Biotechs industry average (3.6x).


Next Steps

Future Growth

How is BioGaia forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

15.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BGL's forecast earnings growth (15.2% per year) is above the savings rate (-0.4%).

Earnings vs Market: BGL's earnings (15.2% per year) are forecast to grow faster than the German market (14.2% per year).

High Growth Earnings: BGL's earnings are forecast to grow, but not significantly.

Revenue vs Market: BGL's revenue (12.9% per year) is forecast to grow faster than the German market (4.2% per year).

High Growth Revenue: BGL's revenue (12.9% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: BGL's Return on Equity is forecast to be high in 3 years time (38.5%)


Next Steps

Past Performance

How has BioGaia performed over the past 5 years?

11.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: BGL has a high level of non-cash earnings.

Growing Profit Margin: BGL's current net profit margins (24.4%) are lower than last year (29%).


Past Earnings Growth Analysis

Earnings Trend: BGL's earnings have grown by 11.9% per year over the past 5 years.

Accelerating Growth: BGL's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: BGL had negative earnings growth (-12.8%) over the past year, making it difficult to compare to the Biotechs industry average (8.7%).


Return on Equity

High ROE: BGL's Return on Equity (36.9%) is considered high.


Next Steps

Financial Health

How is BioGaia's financial position?


Financial Position Analysis

Short Term Liabilities: BGL's short term assets (SEK452.4M) exceed its short term liabilities (SEK124.8M).

Long Term Liabilities: BGL's short term assets (SEK452.4M) exceed its long term liabilities (SEK33.2M).


Debt to Equity History and Analysis

Debt Level: BGL is debt free.

Reducing Debt: BGL has not had any debt for past 5 years.

Debt Coverage: BGL has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: BGL has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet

Inventory Level: BGL has a high level of physical assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if BGL's debt is covered by short term assets.


Next Steps

Dividend

What is BioGaia's current dividend yield, its reliability and sustainability?

2.17%

Current Dividend Yield


Upcoming Dividend Payment

TodayMar 30 2020Ex Dividend DateMay 08 2020Dividend Pay DateMay 14 20206 days from Ex DividendBuy in the next 39 days to receive the upcoming dividend

Dividend Yield vs Market

Notable Dividend: BGL's dividend (2.17%) is higher than the bottom 25% of dividend payers in the German market (1.71%).

High Dividend: BGL's dividend (2.17%) is low compared to the top 25% of dividend payers in the German market (4.98%).


Stability and Growth of Payments

Stable Dividend: BGL's dividend payments have been volatile in the past 10 years.

Growing Dividend: BGL's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its reasonably low payout ratio (34.7%), BGL's dividend payments are well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: BGL's dividends in 3 years are forecast to be covered by earnings (74.2% payout ratio).


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.3yrs

Average management tenure


CEO

Isabelle Valerie Ducellier (50yo)

no data

Tenure

kr3,462,839

Compensation

Ms. Isabelle Valerie Ghislaine Ducellier serves as the Chief Executive Officer and President of BioGaia AB. Ms. Ducellier has been Partner and Consultant at Anian Ab since 2016. Ms. Ducellier has been Visi ...


CEO Compensation Analysis

Compensation vs Market: Isabelle Valerie's total compensation ($USD348.36K) is below average for companies of similar size in the German market ($USD1.40M).

Compensation vs Earnings: Insufficient data to compare Isabelle Valerie's compensation with company performance.


Leadership Team

NamePositionTenureCompensationOwnership
Peter Rothschild
Founder & Chairman1.92yrskr7.16mno data
Isabelle Valerie Ducellier
CEO & Presidentno datakr3.46m0.016% SEK90.2k
Alexander Kotsinas
Executive VP & CFO0.33yrno datano data
Marika Isberg
VP & General Counsel2yrsno datano data
Urban Strindlöv
Executive VP & Sales Director10.17yrsno datano data
Staffan Strömberg
Vice President of Development & Regulatory Affairsno datano datano data
Ulrika Köhler
Vice President of Marketing & Product Developmentno datano datano data
Angelika Kjelldorff
Vice President of Human Resources1.17yrsno datano data
Sebastian Schröder
Executive Vice President of Business Development1.33yrsno data0.0020% SEK11.7k
Peter Persson
Chief Executive Officer of BioGaia Production AB1.17yrsno data0.079% SEK458.5k

1.3yrs

Average Tenure

51yo

Average Age

Experienced Management: BGL's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Peter Rothschild
Founder & Chairman1.92yrskr7.16mno data
David E. Dangoor
Deputy Chairman1.92yrskr400.00k2.56% SEK14.8m
Inger Holmström
Independent Director13.17yrskr200.00k0.0029% SEK16.7k
Peter Elving
Independent Director1.92yrskr200.00kno data
Brit Stakston
Independent Director6.17yrskr200.00kno data
Anthon Jahreskog
Independent Director4.83yrskr200.00kno data
Ewa Björling
Independent Director4.83yrskr200.00kno data

4.8yrs

Average Tenure

69yo

Average Age

Experienced Board: BGL's board of directors are considered experienced (4.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: BGL insiders have sold more shares than they have bought in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

BioGaia AB (publ)'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: BioGaia AB (publ)
  • Ticker: BGL
  • Exchange: DB
  • Founded: 1990
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: kr6.388b
  • Listing Market Cap: kr579.631m
  • Shares outstanding: 17.34m
  • Website: https://www.biogaia.com

Number of Employees


Location

  • BioGaia AB (publ)
  • Kungsbroplan 3
  • Stockholm
  • Stockholm County
  • 112 27
  • Sweden

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BIOG BOM (OMX Nordic Exchange Stockholm)YesClass B SharesSESEKMay 1998
BGLDB (Deutsche Boerse AG)YesClass B SharesDEEURMay 1998
0GTNLSE (London Stock Exchange)YesClass B SharesGBSEKMay 1998
BGAI.FOTCPK (Pink Sheets LLC)YesClass B SharesUSUSDMay 1998
BIOGBsBATS-CHIXE (BATS 'Chi-X Europe')YesClass B SharesGBSEKMay 1998
BIOG.YOTCPK (Pink Sheets LLC)UNSPONSORED ADRUSUSDApr 2013

Biography

BioGaia AB (publ) develops, markets, and sells probiotic products with documented health benefits worldwide. It operates in Pediatrics, Adult Health, and Other segments. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that are used as an ingredient in infant formula. The Adult Health segment provides gut health tablets and oral health lozenges products, as well as cultures, which are used as an ingredient in a dairy product. The Other segment provides packaging solutions. The company offers its products in the areas of baby and child care, including infantile colic, infections, functional abdominal pain, diarrhea, functional constipation, and regurgitation; gut health comprising diarrhoea and constipation; gastrointestinal health consisting of Helicobacter pylori–the gastric ulcer bacterium; and oral health, including gingivitis and periodontitis, caries, and halitosis. The company offers its products under the brand name of BioGaia through pharmacies and retail outlets. BioGaia AB (publ) was founded in 1990 and is headquartered in Stockholm, Sweden. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/03/29 20:58
End of Day Share Price2020/03/27 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.